Why the study?
Reductions in readmission rates credited to Medicare's Hospital Readmissions Reduction Program may be illusory or overstated due to concurrent changes in electronic transaction standards and baseline differences in prior studies' control groups.
Does Medicare's Hospital Readmissions Reduction Program (HRRP) reduce risk-adjusted readmission rates for targeted conditions?
Does Medicare's Hospital Readmissions Reduction Program (HRRP) reduce risk-adjusted readmission rates for targeted conditions?
The apparent reductions in hospital readmissions attributed to Medicare's HRRP may be largely illusory, driven by changes in electronic transaction standards and baseline differences rather than true improvements in care.
Answers are grounded in this paper and cite their sources.
Observed HRRP readmission declines may be artifactual; leaves open true program effects after transaction adjustments.
Medicare's Hospital Readmissions Reduction Program (HRRP) has been credited with lowering risk-adjusted readmission rates for targeted conditions at general acute care hospitals. However, these reductions appear to be illusory or overstated. This is because a concurrent change in electronic transaction standards allowed hospitals to document a larger number of diagnoses per claim, which had the effect of reducing risk-adjusted patient readmission rates. Prior studies of the HRRP relied upon control groups' having lower baseline readmission rates, which could falsely create the appearance that readmission rates are changing more in the treatment than in the control group. Accounting for the revised standards reduced the decline in risk-adjusted readmission rates for targeted conditions by 48 percent. After further adjusting for differences in pre-HRRP readmission rates across samples, we found that declines for targeted conditions at general acute care hospitals were statistically indistinguishable from declines in two control samples. Either the HRRP had no effect on readmissions, or it led to a systemwide reduction in readmissions that was roughly half as large as prior estimates have suggested.
No takes yet. Share an insight, caveat, or question.
Ody et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: